SCHEMBL20138227

SCHEMBL20138227

Cc1ncccc1CN1C(=O)[C@@H](C)Oc2c(F)cc(-c3ccc4c(c3)C(=O)NCC4)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 1/20 0.38
TSHR P16473 3/20 0.37
CDK4 P11802 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK6 Q00534 1/20 0.36
MAPK1 P28482 1/20 0.34
GRIN1 Q05586 2/20 0.34
GRIN2B Q13224 2/20 0.34
PARP10 Q53GL7 5/20 0.34
PARP1 P09874 3/20 0.34
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA5 P31644 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PARP11 Q9NR21 2/20 0.32
PRF1 P14222 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20138151 0.84 CD274 (0.37) CD274CDK4CCNA2CDK2CDK6
SCHEMBL20138141 0.83 CD274 (0.37) CD274CDK4CCNA2CDK2CDK6
SCHEMBL20137962 0.80 MAPK1 (0.36) CD274MAPK1PARP10PARP1GABRG2
SCHEMBL20138161 0.80 CDK4 (0.37) CD274CDK4CCNA2CDK2CDK6
SCHEMBL20138280 0.79 MAPK1 (0.41) CD274TSHRMAPK1PARP10PARP1
SCHEMBL20138313 0.79 MAPK1 (0.41) CD274TSHRMAPK1PARP10PARP1
SCHEMBL20138142 0.77 CDK4 (0.36) CD274CDK4CCNA2CDK2CDK6
SCHEMBL20138050 0.77 TSHR (0.47) TSHRGRIN1GRIN2BGABRA5NPSR1
SCHEMBL20138175 0.77 MAPK1 (0.34) CD274TSHRMAPK1PARP10PARP1
SCHEMBL18305060 0.74 CDK4 (0.41) CD274CDK4CCNA2CDK2CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107873031-B Benzoxazinone derivatives and analogs thereof as modulators of TNF activity UCB生物制药私人有限公司 2021-03-12 CN disclosed
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity UCB BIOPHARMA SPRL (BE) 2019-05-14 US disclosed
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity UCB S.A. (BE) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity TNF, NFKBIA, TNFRSF1A CD274 667/4885TSHR 2169/4885CDK4 3486/4885
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity TNF, TNFRSF1A, NFKBIA CD274 174/4885TSHR 940/4885CDK4 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.